| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | 71.27% | 73.41% | 75.77% | 72.95% |
| Operating Margin | 17.66% | 16.06% | 11.00% | 5.59% | 5.34% | 8.42% | -2.36% | -28.45% | 1.17% | -5.85% | 14.62% | 24.68% |
| EBITDA Margin | 29.43% | 29.23% | 25.43% | 22.75% | 23.74% | 31.16% | 21.76% | 5.19% | 33.93% | 23.78% | 39.77% | 45.71% |
| Net Margin | 1.53% | -0.48% | -6.76% | -2.77% | -11.24% | -6.98% | -20.79% | -49.45% | 27.56% | -24.89% | -2.75% | 11.04% |
| Current Ratio | 1.47 | 0.86 | 1.30 | 1.08 | 1.08 | 1.09 | 1.12 | 1.10 | 1.11 | 1.41 | 1.04 | 1.54 |
| Quick Ratio | 1.08 | 0.62 | 0.94 | 0.80 | 0.89 | 0.86 | 0.94 | 0.85 | 0.87 | 1.11 | 0.80 | 1.19 |
| Debt / Equity | 55.22 | -67.13 | -273.02 | 79.87 | -666.29 | 39.55 | 22.79 | 8.63 | 4.28 | 9.16 | 5.16 | 2.81 |
| ROE | 41.64% | 14.29% | 721.95% | -86.54% | 2788.24% | -92.56% | -157.39% | -147.21% | 40.44% | -73.91% | -4.77% | 16.79% |
| ROA | 0.60% | -0.17% | -2.16% | -0.88% | -3.25% | -1.79% | -5.28% | -12.75% | 6.41% | -5.53% | -0.59% | 3.46% |
| Asset Turnover | 0.39 | 0.36 | 0.32 | 0.32 | 0.29 | 0.26 | 0.25 | 0.26 | 0.23 | 0.22 | 0.21 | 0.31 |
| Book Value / Share | 1.01 | -0.88 | -0.22 | 0.72 | -0.09 | 1.70 | 3.23 | 8.01 | 16.90 | 9.38 | 17.59 | 15.91 |
Bausch Health Companies Inc. is a diversified healthcare company focused on developing, manufacturing, and marketing branded and generic pharmaceuticals, over-the-counter products, and medical devices. Its portfolio spans gastroenterology, neurology, dermatology, and eye health, with a notable legacy from the acquisition of Bausch + Lomb that established a strong footprint in vision care and ophthalmic pharmaceuticals. Operating within the specialty and generic drug segment, the company emphasizes treatments for chronic conditions and niche therapeutic areas where physician-led adoption and patient adherence are critical. Bausch Health serves patients, healthcare professionals, and institutional buyers across global markets through a mix of prescription brands, generics, and consumer health offerings. The firm’s scale—supported by a large employee base—enables integrated R&D, manufacturing, and distribution, positioning it as a meaningful player in cost-sensitive and specialty therapeutics. Financially, it exhibits characteristics of a value-oriented healthcare issuer, reflecting low price-to-sales and active capital allocation underpinned by ongoing operating profitability metrics.